Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Teva Launches Authorized Generic Of Provigil - Quick Facts

RELATED NEWS
Trade TEVA now with 
3/30/2012 8:11 AM ET

Teva Pharmaceutical Industries Ltd. (TEVA: Quote) announced the launch of the authorized generic of Provigil (modafinil). Provigil is marketed by Cephalon, Inc., a wholly owned subsidiary of Teva.

Teva noted that Provigil will continue to be manufactured under the brand product's new drug application at the same facility where it is currently produced. Shipping of the product has begun.

As per the IMS sales data, the brand product had annual sales of around $1.1 billion in US.

Click here to receive FREE breaking news email alerts for Teva Pharmaceutical Industries Limited and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Hewlett-Packard Co. said Wednesday after the markets closed that its second quarter profit fell 32% from last year, hurt by lower revenue and weaker margins amid a slump in PC sales. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations, but its quarterly revenue fell short of analysts' forecast. Stocks showed a substantial downturn over the course of the trading day on Wednesday after seeing some strength in morning trading. Renewed worries about the Federal Reserve tapering its asset purchase program contributed to the sharp pullback by the markets. The major averages climbed off their worst levels going into the close but still ended the day firmly negative. Some members of the Federal Reserve favor scaling back the central bank's $85 billion a month asset purchase program this summer as long as the economy continues to improve, according the the minutes of the Fed's April 30-May 1 meeting. "A number of participants expressed willingness to adjust the...
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.